Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pharmacyte Biotech Inc
(NQ:
PMCB
)
1.590
-0.070 (-4.22%)
Streaming Delayed Price
Updated: 3:46 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pharmacyte Biotech Inc
< Previous
1
2
Next >
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
May 21, 2024
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
November 15, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
November 15, 2023
From
Femasys Inc.
Via
GlobeNewswire
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
October 31, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Final Results of Tender Offer
June 15, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
May 11, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
February 02, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
August 15, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
July 28, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
July 21, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
July 19, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
July 11, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
July 05, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
June 15, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
June 13, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
June 08, 2022
From
PharmaCyte Biotech
Via
Business Wire
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
June 02, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
May 23, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
April 27, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
April 19, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
April 13, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
April 05, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
March 22, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
March 16, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
February 22, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
February 14, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
January 06, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
January 04, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
December 28, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
December 15, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.